Results 1 to 10 of about 29,341 (237)

Wild Type Transthyretin Amyloid Cardiomyopathy Hidden Under Ablation-Refractory Atrial Arrhythmias and the Potential Contribution of Tafamidis in Rhythm Control. [PDF]

J Arrhythm
An octogenarian man with a history of multiple catheter ablation failures for atrial fibrillation and tachycardia was diagnosed with transthyretin amyloid cardiomyopathy. After 1 year of tafamidis therapy, the patient experienced spontaneous restoration of sinus rhythm, and follow‐up image of 99mTc‐pyrophosphate scintigraphy revealed a marked decrease ...
Horie T, Nagata Y, Nozato T, Miyazaki S, Ashikaga T.   +4 more
europepmc   +4 more sources

Technetium-99m-labeled pyrophosphate uptake in the rectum of a patient with wild-type transthyretin cardiac amyloidosis [PDF]

Radiology Case Reports
Wild-type transthyretin amyloidosis is a disease characterized by deposition of transthyretin amyloid protein in systemic organs and tissues, especially the heart, lungs, tenosynovium, and ligaments.
Koji Takahashi, MD, PhD, Daisuke Sasaki, MRT, Shuhei Yamamoto, MD, Nobuhisa Yamamura, MLT, Yushi Utsunomiya, MD, Hiroe Morioka, MD, Shigeki Uemura, MD, Tomoki Sakaue, MD, PhD, Katsuji Inoue, MD, PhD   +8 more
doaj   +2 more sources

Early Progression of Aortic Stenosis Associated With Iatrogenic Variant Transthyretin Amyloidosis After Domino Liver Transplantation

JACC: Case Reports, 2020
We report a 65-year-old man who underwent aortic valve replacement because of severe aortic stenosis associated with de novo iatrogenic variant transthyretin amyloidosis derived from a liver graft extracted from a patient with hereditary transthyretin ...
Yasuhito Hosoda, MD, Mitsuharu Ueda, MD, PhD, Jun Takaki, MD, Ken Okamoto, MD, PhD, Taro Yamashita, MD, PhD, Toshihiro Fukui, MD, PhD   +5 more
doaj   +2 more sources

Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis

Circulation, 2014
Candida Cristina Quarta, Christian Gagliardi, Claudio Rapezzi   +2 more
exaly   +3 more sources

Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review

Biomedicines, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed condition. Although wild-type transthyretin amyloidosis (ATTRwt) is the most common ATTR-CM, hereditary transthyretin amyloidosis (ATTRv) may also occur.
Ana-Maria Merino-Merino, Jorge Labrador-Gomez, Ester Sanchez-Corral, Pedro-David Delgado-Lopez, Jose-Angel Perez-Rivera   +4 more
doaj   +1 more source

Transthyretin, Immature Platelet Fraction, and Mean Platelet Volume in Normotensive and Preeclampsia Pregnancy

Indonesian Biomedical Journal, 2022
BACKGROUND: Transthyretin protein experiences misfolding and aggregation in preeclampsia due to placental ischemia and inflammation. Placental endothelial damage occurring in preeclampsia stimulates the production of larger young platelets in the bone ...
Asri Ragil Kemuning, Herniah Asti Wulanjani, I Edward Kurnia Setiawan Limijadi, Indranila Kustarini Samsuria, Banundari Rachmawati   +4 more
doaj   +1 more source

Transthyretin amyloidosis [PDF]

Nursing, 2020
Abstract: Cardiac amyloidosis is a poorly understood cause of heart failure and is often undiagnosed. Recent advances in diagnostic testing and understanding of the disease have enhanced the ability of clinicians to detect this disease and provide patients with appropriate treatment.
Renáta Aiglová, Miloš Táborský, Pavla Flodrová, Alexander Schee   +3 more
openaire   +3 more sources

Amyloidogenicity assessment of transthyretin gene variants

Annals of Clinical and Translational Neurology, 2022
Objective Hereditary transthyretin‐mediated amyloidosis is a treatable condition caused by amyloidogenic variants in the transthyretin‐gene resulting in severe peripheral neuropathy or cardiomyopathy.
Nicolai B. Grether, Felix Napravnik, Thomas Imhof, Reinhold P. Linke, Jan H. Bräsen, Jessica Schmitz, Maike Dohrn, Christian Schneider, Martin K. R. Svačina, Jörg Stetefeld, Manuel Koch, Helmar C. Lehmann   +11 more
doaj   +1 more source

Transthyretin cardiac amyloidosis

Cardiovascular Research, 2022
AbstractTransthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a
Aldostefano Porcari, Marianna Fontana, Julian D Gillmore   +2 more
openaire   +4 more sources

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight

Case Reports in Medicine, 2021
Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis, Joel Fernandez, Damian A. Laber   +2 more
doaj   +1 more source